MX2018011226A - Tc24-c4, antígeno de vacuna de la enfermedad de chagas con estabilidad mejorada y agregación disminuida. - Google Patents

Tc24-c4, antígeno de vacuna de la enfermedad de chagas con estabilidad mejorada y agregación disminuida.

Info

Publication number
MX2018011226A
MX2018011226A MX2018011226A MX2018011226A MX2018011226A MX 2018011226 A MX2018011226 A MX 2018011226A MX 2018011226 A MX2018011226 A MX 2018011226A MX 2018011226 A MX2018011226 A MX 2018011226A MX 2018011226 A MX2018011226 A MX 2018011226A
Authority
MX
Mexico
Prior art keywords
improved stability
vaccine antigen
chagas disease
disease vaccine
decreased aggregation
Prior art date
Application number
MX2018011226A
Other languages
English (en)
Inventor
Ajibola Asojo Oluwatoyin
Elena Bottazzi Maria
Olivier Dumonteil Eric
Jay Hotez Peter
M Hudspeth Elissa
Pollet Jeroen
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Publication of MX2018011226A publication Critical patent/MX2018011226A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56905—Protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Las modalidades de la divulgación se refieren a métodos y composiciones relacionadas con una composición inmunogénica particular que comprende la proteína Tc24 de Trypanosoma cruzi que tiene sustituciones en cuatro residuos de cisteína para mejorar la estabilidad y/o disminuir la agregación. Las composiciones son útiles para inmunoprotección contra las enfermedades causadas por T. cruzi, particularmente en mamíferos susceptibles a la misma.
MX2018011226A 2016-03-14 2017-03-14 Tc24-c4, antígeno de vacuna de la enfermedad de chagas con estabilidad mejorada y agregación disminuida. MX2018011226A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662308054P 2016-03-14 2016-03-14
PCT/US2017/022317 WO2017160849A1 (en) 2016-03-14 2017-03-14 Tc24-c4, a chagas disease vaccine antigen with improved stability and decreased aggregation

Publications (1)

Publication Number Publication Date
MX2018011226A true MX2018011226A (es) 2019-05-16

Family

ID=59851379

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011226A MX2018011226A (es) 2016-03-14 2017-03-14 Tc24-c4, antígeno de vacuna de la enfermedad de chagas con estabilidad mejorada y agregación disminuida.

Country Status (3)

Country Link
BR (1) BR112018068544A2 (es)
MX (1) MX2018011226A (es)
WO (1) WO2017160849A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240108707A1 (en) * 2019-10-17 2024-04-04 Baylor College Of Medicine Chagas disease vaccine antigens with improved stability and decreased aggregation
CN118108790A (zh) * 2024-03-25 2024-05-31 中国农业大学 一种具glp-1受体激动剂活性的乳清蛋白源降血糖肽的制备及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0976763B1 (en) * 1998-07-30 2003-11-05 Innogenetics N.V. Antigens and immunoassays for diagnosing Chagas' disease
US7749717B2 (en) * 2006-10-19 2010-07-06 Abbott Laboratories Methods for the detection and diagnosis of Trypanosoma cruzi infection
CA2710761C (en) * 2007-12-27 2019-01-08 Abbott Laboratories Anti-t. cruzi antibodies and methods of use
TWI690322B (zh) * 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用

Also Published As

Publication number Publication date
WO2017160849A1 (en) 2017-09-21
BR112018068544A2 (pt) 2019-04-24

Similar Documents

Publication Publication Date Title
BR112018012873A2 (pt) vacina de vírus zika
EA201790630A1 (ru) Способы получения рибозидов
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201690556A1 (ru) Способы и фармацевтические композиции для лечения вызванных вирусом гепатита в инфекций
EA201591524A1 (ru) Производные 2-аминопиримидина для лечения вирусных инфекций
EA201692512A1 (ru) Способы и композиции для лечения синтетическими наноносителями и ингибиторами иммунной контрольной точки
EA201691216A1 (ru) Композиции линаклотида с замедленным высвобождением
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201792407A2 (ru) Композиции, содержащие буфер, составы вакцин, которые содержат композиции, содержащие буфер, и пути их применения
PH12018000197A1 (en) Hand, foot, and mouth vaccines and methods of manufacture and use thereof
EA201492214A1 (ru) Ингибиторы вируса гепатита с
EA202090683A3 (ru) Способы и композиции для лечения рака
MX2021010060A (es) Produccion de virus en huevos aviares.
EA201790239A1 (ru) Молекула-носитель для антигенов
MX2020004542A (es) Metodo para inactivar el virus del zika y para determinar la inactivacion total.
EA201790655A1 (ru) Новые активаторы растворимой гуанилатциклазы и их применение
EA202191513A1 (ru) Снижение вязкости фармацевтических составов
CU20170044A7 (es) Método mejorado para producir una composición de partículas enterovirales a través de la inactivación del enterovirus y la adsorción en coadyuvantes
CU20180025A7 (es) Proceso de preparación de una vacuna tetravalente atenuada contra el virus del dengue
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201690857A1 (ru) Конъюгатные вакцины на основе сальмонеллы
MX2019007252A (es) Metodos y composiciones para vacunas del virus del dengue.
EA201691638A1 (ru) Новые способы индуцирования иммунного ответа
EA201691741A1 (ru) Фармацевтическая композиция
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба